2014 56th ASH Annual Meeting - účast ČR

101. Red Cells and Erythropoiesis, Structure and Function, Metabolism, and Survival, Excluding Iron: Poster III

102. Regulation of Iron Metabolism: Poster III

201. Granulocytes, Monocytes and Macrophages: Poster II

203. Lymphocytes, Lymphocyte Activation and Immunodeficiency, including HIV and other Infection: Poster

311. Disorders of Platelet Number or Function: Poster

501. Hematopoietic Stem and Progenitor Biology: Poster III

601. Chromosomal Rearrangements and DNA Repair: Poster I

602. Disordered Gene Expression in Hematologic Malignancy, including Disordered Epigenetic Regulation: Molecular Mechanisms of Myeloid Malignancy

602. Disordered Gene Expression in Hematologic Malignancy, including Disordered Epigenetic Regulation: Poster

605. Molecular Pharmacology, Drug Resistance – Lymphoid and Other Diseases: Poster

612. Acute Lymphoblastic Leukemia: Clinical Studies II

613. Acute Myeloid Leukemia: Clinical Studies: Pathophysiology and Prognosis

616. Acute Myeloid Leukemia: Novel Therapy, excluding Transplantation: Poster I

617. Acute Myeloid Leukemia: Biology, Cytogenetics and Molecular Markers in Diagnosis and Prognosis: Genetic Mutations in Association: Novel Insights

617. Acute Myeloid Leukemia: Biology, Cytogenetics and Molecular Markers in Diagnosis and Prognosis: Insights From NGS And Functional Studies

617. Acute Myeloid Leukemia: Biology, Cytogenetics and Molecular Markers in Diagnosis and Prognosis: Poster

Číslo abstraktu: 2348
Kategorie: Maligní lymfomy a leukémie; Nádorová biologie/imunologie/genetika a buněčná terapie

618. Acute Lymphoblastic Leukemia: Biology, Cytogenetics and Molecular Markers in Diagnosis and Prognosis: Poster

618. Acute Lymphoblastic Leukemia: Molecular Genetic Studies

622. Non-Hodgkin Lymphoma: Biology, excluding Therapy: Poster I

623. Lymphoma: Chemotherapy, excluding Pre-Clinical Models: Hodgkin Lymphoma/ T-cell Lymphoma

623. Lymphoma: Chemotherapy, excluding Pre-Clinical Models: Poster

624. Lymphoma: Therapy with Biologic Agents, excluding Pre-Clinical Models: Aggressive NHL

625. Lymphoma: Pre-Clinical – Chemotherapy and Biologic Agents II

632. Chronic Myeloid Leukemia: Outcomes With TKI Therapy

632. Chronic Myeloid Leukemia: Prognosis and Therapy

632. Chronic Myeloid Leukemia: Therapy: Poster

632. Chronic Myeloid Leukemia: Therapy: TKI cessation, monitoring and resistance

634. Myeloproliferative Syndromes: Clinical: Poster II

637. Myelodysplastic Syndromes – Clinical Studies: Molecular Characterization and Lower Risk MDS

637. Myelodysplastic Syndromes – Clinical Studies: Poster

641. CLL: Biology and Pathophysiology, excluding Therapy: Advances in (Immuno)genetics

641. CLL: Biology and Pathophysiology, excluding Therapy: Poster

642. CLL: Therapy, excluding Transplantation: Phase 3 Trials and More

642. CLL: Therapy, excluding Transplantation: Poster

651. Myeloma: Biology and Pathophysiology, excluding Therapy: Genomics

651. Myeloma: Biology and Pathophysiology, excluding Therapy: Mutational Landscape and Transcriptome Editing: Prognostic and Predictive Impact in Myeloma

651. Myeloma: Biology and Pathophysiology, excluding Therapy: Poster

653. Myeloma: Therapy, excluding Transplantation I

653. Myeloma: Therapy, excluding Transplantation II

653. Myeloma: Therapy, excluding Transplantation: Poster

711. Cell Collection and Processing: Poster III

721. Clinical Allogeneic Transplantation: Conditioning Regimens, Engraftment and Acute Transplant Toxicities: Novel Conditioning Regimens

721. Clinical Allogeneic Transplantation: Conditioning Regimens, Engraftment and Acute Transplant Toxicities: Personalizing Transplant Outcomes

731. Clinical Autologous Transplantation: Results: Clinical Results in Plasma Cell Dyscrasias 2

731. Clinical Autologous Transplantation: Results: Poster I

731. Clinical Autologous Transplantation: Results: Poster II

731. Clinical Autologous Transplantation: Results: Poster III

732. Clinical Allogeneic Transplantation: Results: Poster I

732. Clinical Allogeneic Transplantation: Results: Poster II

802. Chemical Biology and Experimental Therapeutics: Poster I

902. Health Services and Outcomes Research – Malignant Diseases: New/Refined Prognostic Schemes/Pharmacoeconomics